Wider access to antivenom in Brazil’s Amazon is a worthy investment, study finds

urban hospitals, and many people bitten by venomous snakes in remote parts of the state suffer serious complications or even die before they can reach treatment.

The new study, conducted by scientists and physicians from Duke University and two Brazilian institutions, evaluated the cost-effectiveness of making antivenom available across more hospitals and community health centers in the region. The results, published in the January 2024 issue of The Lancet Regional Health—Americas, show such a step would be a worthy investment.

“We believe that ours is the first study to evaluate the health and economic benefits of increasing the accessibility of snake antivenom in Latin America,” says João Ricardo Nickenig Vissoci, Ph.D., chief of the Duke Department of Emergency Medicine’s Division of Translational Health Sciences and the study’s lead author.

The researchers evaluated three strategies for expanding access to snake antivenom in Amazonas. One model made antivenom available in 95% of the state’s hospitals, while a second model tested availability in 95% of community health centers, which are more widely distributed in rural areas. The third model expanded access to both hospitals and community health centers.

All three models produced net economic benefits worth millions of U.S. dollars and prevented deaths and disabilities, as measured by disability-adjusted life-years (DALYs), which count the number of years of life that are impacted by or lost due to disease or injury. According to the research, expanding access to both hospitals and community health centers would produce the largest benefits, averting up to 3,922 DALYs while yielding economic benefits of up to US$8.98 million. The cost of expanding access was around $328 for every DALY averted.

Despite Brazil’s robust production of antivenom drugs, the findings show that lack of access to antivenom can have a significant impact on the regions where most snakebites occur. “Policies that promote access to snake antivenom should be a priority to countries with an elevated snakebite envenoming burden,” says Vissoci, who is also part of the Duke Global Health Institute.

The next step for the researchers is to begin trials making antivenom available at community health centers in Amazonas. Community care providers can be trained to administer antivenom safely and effectively, the researchers say.

The new research is consistent with the recommendations of a World Health Organization working group on snakebite envenoming, which emphasized that sustainable strategies for dealing with snakebites depend on more than therapeutics, notes Charles J. Gerardo, M.D., interim chair of Duke’s Department of Emergency Medicine and joint senior author of the study. “It depends on the decentralized distribution of treatment, as well as on the infrastructure and knowledge to deliver it.”

More information:
Armand Zimmerman et al, Scaling up antivenom for snakebite envenoming in the Brazilian Amazon: a cost-effectiveness analysis, The Lancet Regional Health—Americas (2023). DOI: 10.1016/j.lana.2023.100651